Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 246

Efforts to study the early stages of the coronavirus pandemic have received help from a surprising source. A biologist in the United States has ‘excavated’ partial SARS-CoV-2 genome sequences from the beginnings of the pandemic’s probable epicentre in Wuhan, China, that were deposited — but later removed — from a US government database.

The partial genome sequences address an evolutionary conundrum about the early genetic diversity of the coronavirus SARS-CoV-2, although scientists emphasize that they do not shed light on its origins. Nor is it fully clear why researchers at Wuhan University asked for the sequences to be removed from the Sequence Read Archive (SRA), a repository for raw sequencing data maintained by the National Center for Biotechnology Information (NCBI), part of the US National Institutes of Health (NIH).

Partial SARS-CoV-2 sequences from early outbreaks in Wuhan were removed from a US government database by the scientists who deposited them.

Read more | >

Residents of Abusir el-Meleq, an ancient Egyptian city south of Cairo, the men died between 1,380 B.C.E. and 450 C.E. A team from Parabon NanoLabs presented the trio’s facial reconstructions at the International Symposium on Human Identification in September.

“[T]his is the first time comprehensive DNA phenotyping has been performed on human DNA of this age,” says Parabon, a Virginia-based company that typically uses genetic analysis to help solve cold cases, in a statement.

To approximate the men’s faces, researchers used DNA phenotyping, which predicts individuals’ physical appearance based on genetic markers. (Phenotyping can suggest subjects’ skin, hair and eye color, but as Caitlin Curtis and James Hereward wrote for the Conversation in 2,018 the process has its limitations.) The team determined the mummies’ other characteristics through examination of their physical remains, reports Hannah Sparks for the New York Post.

Read more | >

And, depending on how further studies progress, it could be implemented via gene therapy.

Early-stage pancreatic cancer has a ‘reset button’

“These findings open up the possibility of designing a new gene therapy or drug because now we can convert cancerous cells back into their normal state,” said Professor Bumsoo Han of Purdue’s mechanical engineering, who is also the program leader for the university’s Center for Cancer Research, in a blog post shared on the university’s official website. Han has also received a courtesy appointment in biomedical engineering, according to the post. The new time machine (speaking figuratively) from Han’s lab is a lifelike reproduction of a specific structure of the pancreas, called the acinus, which secretes and produces digestive enzymes into the small intestine. When pancreatic cancer strikes, it typically comes from chronic inflammation, which is caused by a mutation that tricks the digestive enzymes to begin digesting the pancreas itself. This is bad.

Read more | >

Brains aren’t the easiest of organs to study, what with their delicate wiring and subtle whispering of neurotransmitter messages. Now, this research could be made a little easier, as we’ve learned we can swap some critical chemical systems with the host animal being none the wiser.

In a proof-of-concept study run by a team of US researchers, the microscopic worm Caenorhabditis elegans was genetically gifted pieces of a nervous system taken from a radically different creature – a curious freshwater organism known as Hydra.

The swap wasn’t unlike teaching a specific brain circuit a foreign language, and finding it performs its job just as well as before.

Read more | >

Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer.

Scientists have unveiled new maps of the protein networks underlying different types of cancer, offering a potentially clearer way to see what’s driving the disease and to find therapeutic targets.

Sequencing the genetic information of tumors can provide a trove of data about the mutations contained in those cancer cells. Some of those mutations help doctors figure out the best way to treat a patient, but others remain more of a mystery than a clear instruction manual. Many are exceedingly rare, or there are so many mutations it’s not clear what’s fueling the cancer.

Read more | >

DNA extracted from ancient Egyptian mummies is offering an intriguing glimpse at what three men might’ve looked like when they hung out in the Fertile Crescent more than 2,000 years ago.

The genetic sleuthing led to highly detailed 3D constructions of a trio from an ancient Nile community known as the Abusir el-Meleq who are estimated to have lived between 2,023 and 2,797 years ago.

The images result from DNA phenotyping, which predicts a person’s physical characteristics based on genetic data. The re-creations mark the first time comprehensive DNA phenotyping has been performed on human DNA this old, according to Virginia-based Parabon NanoLabs, the company behind the images. Parabon typically taps DNA phenotyping to help solve criminal cases.

Read more | >

New research exploring theories of aging has found that small mutations accumulating in DNA are unlikely to be fully responsible for this process.

The research, a collaboration between the Wellcome Sanger Institute, University of Birmingham, University of Edinburgh and others, found that and tissues can accumulate many more than are normally present, without the body showing the features associated with aging.

The new study, published today (30 September) in Nature Genetics, compared DNA taken from individuals with inherited mutations in genes involved in DNA replication with DNA from individuals who have normal versions of these genes. The researchers aimed to understand the impact of defective DNA replication on and features associated with aging. The results suggest that build-up of mutations in is unlikely to be the only factor in the development of age-related disease, adding to the ongoing debate about the causes of aging.

Read more | >

Genetic diseases are a compelling target for viral gene therapy. One condition that scientists are investigating to see if they can treat with gene therapy is a rare genetic disease called Leber congenital amaurosis, or LCA is a progressive condition that disables critical cells within the retina. The damage begins at birth: it eventually robs patients of central vision and color perception, often rendering them legally blind. But there may be another way. On Wednesday, researchers presented evidence from a breakthrough gene-editing experiment that restored some color vision to patients with LCA vision loss.

CRISPR is already under investigation as a gene therapy for blood disorders like sickle cell disease and beta-thalassemia. It may well have other uses, such as treating cancer by editing mutated DNA. But the process is not without its hurdles. Treatments for blood disorders like these involve taking cells from the patient’s body, changing them in vitro in the lab, and then re-infusing them back into the patient’s body. That works great for blood, which you can take out, filter, and put back in with relatively few consequences.

But because LCA is a disease of the retina, you can’t just take out cells and then infuse them back in. The retina is a delicate, multilayered membrane that resents any disturbance. The eye also has a system of physical defenses not unlike the blood-brain barrier. Furthermore, the immune system sometimes responds with extreme prejudice to eye injuries or infections, to the point of causing an actual autoimmune disease where the body attacks its own eyes. How, then, could researchers get the CRISPR treatment into the retina, past the body’s ferocious defenses and without further damage?

Read more | >

(https://www.linkedin.com/in/evelyne-yehudit-bischof/) is an expert in internal medicine and oncology, with a focus on preventative and precision medicine, bio-gerontology, and geronto-oncology.

Dr. Bischof is deeply passionate about next-generation medical technology, and the applications of artificial intelligence for biomedical research and practice.

Dr. Bischof spent a decade practicing medicine and performing translational research in Switzerland, US, and China.

Dr. Bischof is a medical doctor with an MD from Max Planck Institute for Molecular Biology and Genetics, and interned at Columbia University, Harvard MGH, and Beth Israel Medical Deaconess.

Continue reading “Dr. Evelyne Bischof, MD — Advancing The Frontiers Of Preventative And Precision Longevity Medicine” | >